Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Symkevi“
Suchtreffer
Begriffe & Kennungen
Symkevi · 4.5 · Examples of strong CYP3A inducers include rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin, and
Eintrag öffnenSymkevi · 4.5 · Examples of strong CYP3A inhibitors include ketoconazole, itraconazole, posaconazole, and voriconazole, telith
Eintrag öffnenSymkevi · 4.5 · Hormonal contraceptives
Eintrag öffnenSymkevi · 4.5 · In vitro studies showed that ivacaftor is not a substrate for OATP1B1, OATP1B3, or P-gp. Ivacaftor and its met
Eintrag öffnenSymkevi · 4.5 · In vitro studies showed that tezacaftor is a substrate for the uptake transporter OATP1B1, and efflux transpor
Eintrag öffnenSymkevi · 4.5 · Interaction studies have only been performed in adults.
Eintrag öffnenSymkevi · 4.5 · Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) is recommended
Eintrag öffnenSymkevi · 4.5 · Medicinal products affected by tezacaftor and ivacaftor
Eintrag öffnenSymkevi · 4.5 · Medicinal products affecting the pharmacokinetics of tezacaftor and ivacaftor
Eintrag öffnenSymkevi · 4.5 · OATP1B1 substrates
Eintrag öffnenSymkevi · 4.5 · Paediatric population
Eintrag öffnenSymkevi · 4.5 · Physiologically based pharmacokinetic modeling suggested co-administration with fluconazole, a moderate CYP3A
Eintrag öffnenSymkevi · 4.5 · Potential for tezacaftor/ivacaftor to interact with transporters
Eintrag öffnenSymkevi · 4.5 · Symkevi in combination with ivacaftor has been studied with an estrogen/progesterone oral contraceptive and wa
Eintrag öffnenSymkevi · 4.5 · Symkevi in combination with ivacaftor has been studied with pitavastatin, an OATP1B1 substrate, and was found
Eintrag öffnenSymkevi · 4.5 · Tezacaftor and ivacaftor are substrates of CYP3A (ivacaftor is a sensitive substrate of CYP3A). Concomitant us
Eintrag öffnenSymkevi · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenSymkevi · 4.8 Undesirable effects · 1
Eintrag öffnenSymkevi · 4.8 · 10 During the 24-week, open-label phase 3 study in patients aged 6 to less than 12 years (study 661-113 part B
Eintrag öffnenSymkevi · 4.8 · 9 Table 4: Adverse reactions MedDRA System Organ Adverse reactions Frequency Class Upper respiratory tract inf
Eintrag öffnen